Clinical Trial Update: The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating natalizumab's effects on vaccination response and lymphocyte subsets in relapsing multiple sclerosis; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2011-07-29